EUVIMEDEUVIMED entdecken
Crossref

Inflammatory cytokines in pediatric pneumonia: evidence landscape, clinical applications, and future directions—a narrative review

Liang Li, Junyao Li, Qin Li

Translational Pediatrics · 2026-11 · 15 (11) · 473-473

DOI: 10.21037/tp-2026-0787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Pediatrics, 2026-11. Verfasst von Liang Li und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective: Pediatric pneumonia remains a major cause of childhood morbidity and mortality, particularly in low- and middle-income countries. Early identification of children at risk of respiratory failure, pediatric intensive care unit (PICU) admission, or other critical outcomes remains challenging. Inflammatory cytokines have been investigated as candidate biomarkers for etiologic characterization, severity assessment, prognosis, and prediction of deterioration. This narrative review aimed to synthesize the pediatric clinical evidence, distinguish concurrent severity associations from prognostic and prospective predictive applications, and identify priorities for clinical translation.

Methods

PubMed, Web of Science, Embase, and Scopus were searched from database inception to 25 June 2026. English-language studies involving pediatric pneumonia, inflammatory cytokine measurements, and clinically relevant outcomes were considered. Twenty-three original pediatric pneumonia studies provided direct clinical evidence. Additional adult, pediatric critical illness, experimental, review, and methodological publications were used only as indirect contextual evidence. Findings were synthesized narratively according to the temporal relationship between cytokine measurement and outcome.Key Content and Findings: Interleukin-6 (IL-6), IL-8, and IL-10 showed the most consistent associations with inflammatory severity already present at or near the time of sampling. Evidence for tumor necrosis factor-alpha (TNF-α), IL-1β, interferon-gamma (IFN-γ), and IL-17A was more limited, context-dependent, or pathogen-specific. Prognostic evidence in established critical illness was sparse. True prospective prediction was limited to one Mycoplasma pneumoniae pneumonia cohort in which admission IL-6 and IL-10 were associated with subsequent refractory disease. No externally validated cytokine-based model was identified for predicting PICU transfer, invasive mechanical ventilation, pediatric acute respiratory distress syndrome (ARDS), shock, or mortality. Heterogeneity in populations, sampling time, specimen type, assay platform, and outcome definitions limited cross-study comparability.

Conclusions

Current evidence supports inflammatory cytokines mainly as investigational markers of concurrent disease severity rather than validated predictors of subsequent deterioration. Cytokine measurements should not replace routine clinical assessment, physiological monitoring, or microbiological evaluation. Future research should prioritize prospective pre-deterioration sampling, harmonized laboratory methods, integration with routine clinical variables, independent external validation, and assessment of clinical utility.

Zitieren

APA

Li, L., Li, J., & Li, Q. (2026). Inflammatory cytokines in pediatric pneumonia: evidence landscape, clinical applications, and future directions—a narrative review. Translational Pediatrics, 15(11), 473-473. https://doi.org/10.21037/tp-2026-0787

Vancouver

Li L, Li J, Li Q. Inflammatory cytokines in pediatric pneumonia: evidence landscape, clinical applications, and future directions—a narrative review. Translational Pediatrics. 2026;15(11):473-473. doi:10.21037/tp-2026-0787

BibTeX
@article{Li2026,
  author = {Li, Liang and Li, Junyao and Li, Qin},
  title = {Inflammatory cytokines in pediatric pneumonia: evidence landscape, clinical applications, and future directions—a narrative review},
  journal = {Translational Pediatrics},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {473--473},
  doi = {10.21037/tp-2026-0787}
}
Kostenlos starten →